Renoux G
Comp Immunol Microbiol Infect Dis. 1986;9(2-3):121-9. doi: 10.1016/0147-9571(86)90003-2.
Immunotherapeutic agents (IMT) are intended to restore or reequilibrate a faltering immune system. Levamisole was the first chemically defined IMT endowed with immunomodulatory effects. In order to clarify the mechanisms of its ambivalent activities, thiocompounds were tested for their ability to modify immune responses. All thiomidazoles are immunomodulatory drugs which dose-dependent effectiveness is related with the cholinergic-like influence of the imidazole moiety. The findings suggest also a relationship among thiodrugs between chemical structure and influence on the immune system. These studies lead to the development of sodium diethyldithiocarbamate (Imuthiol), as a non-toxic immunostimulant agent, specifically active on the T-cell lineage. Our studies unequivocally put forth on the specific requirements that are essential to characterize a potential IMT prior to clinical release: in vivo activities no immunosuppression through prolonged administration no antigenicity or hapten-like activity no carcinogenicity or tumor-promoting influence experimental route of administration related to that in humans assays in various animal strains pharmacokinetics chemical characterization known toxicities, teratogenesis, and mutagenesis assays on models of cancer, autoimmune diseases, immunodeficiencies, and infections. The results will allow to determine a range of doses, and predict most direct and secondary effects. They will also specify whether the agent is an adjuvant, a reticulostimulant, an immunomodulatory, an immunostimulatory, an immunorestorative, or an immunoregulating drug. Clinicians will therefore be provided with the data which are essential to perform useful clinical testing.
免疫治疗药物(IMT)旨在恢复或重新平衡衰退的免疫系统。左旋咪唑是首个具有免疫调节作用的化学合成IMT。为阐明其双重活性的机制,对硫化合物调节免疫反应的能力进行了测试。所有硫代咪唑都是免疫调节药物,其剂量依赖性疗效与咪唑部分的胆碱能样影响有关。研究结果还表明硫代药物的化学结构与对免疫系统的影响之间存在关联。这些研究促成了二乙基二硫代氨基甲酸钠(Imuthiol)的研发,它是一种无毒的免疫刺激剂,对T细胞谱系具有特异性活性。我们的研究明确提出了在临床应用前确定潜在IMT所必需的特定要求:体内活性、长期给药无免疫抑制作用、无抗原性或类半抗原活性、无致癌性或促肿瘤影响、与人体相关的实验给药途径、在各种动物品系中的试验、药代动力学、化学特征、已知毒性、致畸性和诱变性试验,以及在癌症、自身免疫性疾病、免疫缺陷和感染模型中的试验。这些结果将有助于确定一系列剂量,并预测最直接和次要的效应。它们还将明确该药物是佐剂、网状内皮系统刺激剂、免疫调节剂、免疫刺激剂、免疫恢复剂还是免疫调节药物。因此,临床医生将获得进行有效临床测试所需的数据。